Biography


Biography

<< Back

Gary Patou

Director
Dr. Patou has served as a member of our Board since January 2004. Dr. Patou serves as a Chief Medical Officer at Star Therapeutics Inc. since August 2020. He is a member of the board of directors and Chief Medical Officer for BioIntervene Inc., beginning in January 2019. Dr. Patou has been an Advisor at MPM Capital, a venture capital fund focused on life sciences companies, since August 2020. Previously, Dr. Patou was an Executive Partner at MPM Capital from 2005 until 2020, and has served as interim Chief Medical Officer in various MPM portfolio companies, including at Blade Therapeutics between October 2018 and December 2020. Prior to joining MPM, Dr. Patou was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals Corp. from February 2004 to April 2005 following its merger with GeneSoft Pharmaceuticals, Inc. Prior to GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company’s pharmaceutical development projects. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine and received his B.Sc. from University of London and his M.D. from University College London.